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Abstract 
Objectives: Bacterial biofilms represent a major impediment to healing in chronic wounds, 
and are largely refractory to antibacterial agents currently used in wound management. From 
a repurposing screen of compounds considered safe for topical application in humans, we 
report the identification of bronopol and bronidox as broad-spectrum antibiofilm agents and 
potential candidates for reducing biofilm burden in chronic wounds. 
Methods: Antibiofilm activity was assessed by viable counting against single-species biofilms 
of Staphylococcus aureus and Pseudomonas aeruginosa in the Calgary Biofilm Device (CBD) 
and against mixed-species biofilms of the two organisms growing on nitrocellulose disks.  
Results: The personal care product preservatives, bronopol and bronidox, exhibited broad-
spectrum antibiofilm activity that encompassed the two major wound pathogens, S. aureus 
and Ps. aeruginosa. When impregnated into gauze dressings at their existing maximum 
authorised concentrations for safe use and placed onto an established mixed-species biofilm, 
bronopol and bronidox completely eradicated Ps. aeruginosa and achieved a ~5 log10 
reduction in the S. aureus population. The antibiofilm action of bronopol and bronidox was 
attributed to their ability to kill slow- or non-growing bacteria found in biofilms, and both 
compounds exhibited synergistic antibiofilm effects in combination with established wound-
treatment agents.  
Conclusions: Bronopol and bronidox kill bacteria regardless of growth state, a property that 
endows them with broad-spectrum antibiofilm activity. Since this effect is observed at 
concentrations authorised for use on human skin, these compounds represent promising 
candidates for the treatment of chronic wounds. 
 
  
Introduction 
Biofilms are spatially-structured communities of microorganisms encased within a self-
produced polymeric matrix, and are a feature of >80% of bacterial infections in humans. 1 
Infections involving a substantial biofilm component are extremely difficult to treat, since the 
nature of this structure acts to thwart the very processes that are ordinarily relied upon to 
achieve resolution of a bacterial infection; the extracellular matrix physically shields the 
biofilm residents from components of the ŚŽƐƚ ?Ɛ ŝŵŵƵŶĞ ƐǇƐƚĞŵ, whilst the slow-or non-
growing (SONG) status of biofilm-associated bacteria renders them refractory to killing by 
most antibacterial drugs. 1,2  
 
A common biofilm-associated disease that is particularly challenging to manage is the chronic 
wound. Biofilms are a near universal feature of such wounds, 3 and their presence is 
associated with persistent inflammation and a failure to heal. 4, 5 It is estimated that over 1 
million adults in the UK are affected by chronic wounds, with treatment of this condition costing 
the NHS £3.2 billion each year. 6 Grave complications are associated with chronic wounds that are 
not adequately managed and persist; in patients with comorbidities such as diabetes, lower 
extremity amputation may be required, 7 and the five year mortality following such an 
intervention stands at 50%. 8 With our ageing population and an increasing incidence of 
diabetes and obesity, the number of individuals affected by chronic wounds is set to rise. 9, 10 
To help address the current difficulties that this condition presents, it will be vital to identify 
agents that are capable of reducing or eradicating the biofilm burden associated with the 
wound bed, thereby removing a major impediment to healing. 
 
In recent studies, we have reported several potent antibiofilm compounds with potential for 
topical treatment of human skin infections involving a biofilm component. 11, 12 Our approach 
to identifying such agents has involved evaluating the antibiofilm activity of compounds that 
are already in human use for other purposes, 11, 12 and which are therefore considered safe 
for topical application. Such a repurposing strategy, which takes as its starting point chemicals 
with established safety profiles, potentially offers an accelerated route by which new 
antibiofilm agents could reach the clinic.  An important limitation of the antibiofilm 
compounds we have identified to date is their narrow spectrum of activity, which is 
exclusively directed towards Gram-positive bacteria such as Staphylococcus aureus. In view 
of the fact that chronic wound biofilms often comprise multiple bacterial species, including 
Gram-negative genera, broad-spectrum activity would represent a highly desirable property 
in a candidate antibiofilm compound for use in wound management.  
 
Here we report the identification and characterization of two related compounds, bronopol 
(2-Bromo-2-nitro-1,3-propanediol) and bronidox (5-Bromo-5-nitro-1,3-dioxane)(Figure 1), 
that exhibit broad spectrum antibiofilm activity, and which therefore represent promising 
candidates for topical reduction/ removal of the chronic wound biofilm. 
 
 
  
Materials and Methods 
General aspects. S. aureus SH1000 13, 14 and Ps. aeruginosa PAO1 15 were routinely propagated 
using cation-adjusted Mueller-Hinton broth (MHB) and agar (MHA) (both from Sigma Aldrich, 
Poole, UK) at 37°C. Antibiotics, antiseptics and other chemicals were also from Sigma Aldrich, 
whilst commercial wound treatment agents were from Williams Medical (Rhymney, UK). 
Evaluation of antibacterial activity against planktonic cultures. MICs were determined 
according to the Clinical and Laboratory Standards Institute broth microdilution guidelines. 16 
Time-kill studies were performed with both exponential- and non-growing (stationary phase) 
cultures of S. aureus SH1000, essentially as previously described. 12 
Evaluation of antibiofilm activity and mode of action. Minimum Biofilm Eradication 
Concentrations (MBECs), defined as the lowest concentration of antibacterial agent required 
to completely sterilize the biofilm, were determined using the Calgary Biofilm Device (CBD; 
Nunc A/S, Roskilde, Denmark). 17 
The cellulose disk biofilm model 18 was modified to assess the activity of bronopol and 
bronidox against larger, dual-species biofilms. Briefly, 25mm mixed cellulose disks (Millipore, 
Watford, UK), preconditioned overnight with 4% human plasma (Sera Laboratories, West 
Sussex, UK), were inoculated with saturated cultures of P. aeruginosa PAO1 (1.8 mL) and S. 
aureus SH1000 (200 µL) and placed on Brain Heart Infusion agar (BHIA). ĨƚĞƌ  ? ? ŚŽƵƌƐ ?
incubation at 37°C, the disks were transferred to fresh BHIA and challenged either with sterile 
gauze saturated with bronopol and bronidox at their maximum authorised concentrations 
(0.1% w/v), or with a commercial wound treatment agent. After a further 24 hours ?ŝŶĐƵďĂƚŝŽŶ
at 37°C,  adherent cells were released from the disks 18 and bacteria enumerated by plating 
onto MHA (to achieve a total count) and Mannitol Salt Agar (Sigma Aldrich, Poole, UK) (for 
enumeration of staphylococci). 19 
The antibiofilm mode of action of bronopol and bronidox was investigated essentially as 
described. 12, 20 Briefly, S. aureus SH1000 biofilms were grown in MHB in 96-well microtitre 
plates, exposed to bronopol and bronidox at 16X MBEC for varying lengths of time, and 
biofilm matrix material quantified using the fluorescent stain, SyproRuby®(Invitrogen, UK). In 
parallel experiments, bacteria were recovered from biofilms treated with bronopol and 
bronidox and enumerated by plating onto MHA. 12 
To detect synergistic interactions between bronopol/ bronidox and established wound 
agents, a checkerboard assay 21 was employed to determine fractional biofilm eradication 
concentration (FBEC) indices.  
  
Results and discussion 
Ongoing screening of compounds found in personal care products against biofilms of the most 
prevalent Gram-positive and Gram-negative pathogens occurring in chronic wounds (S. 
aureus and Ps. aeruginosa, respectively 22) identified the related bromine-containing 
preservative agents bronopol and bronidox (Figure 1) as broad-spectrum antibiofilm agents. 
Against biofilms of both Ps. aeruginosa PAO1 and S. aureus SH1000 grown on the Calgary 
Biofilm Device (CBD), bronidox exhibited MBECs of 128 mg/L, whilst bronopol showed greater 
potency against Ps. aeruginosa biofilms (MBEC of 64 mg/L) compared with S. aureus biofilms 
(MBEC of 256 mg/L). Bronopol and bronidox also demonstrated antibacterial activity against 
planktonic cultures of Ps. aeruginosa, S. aureus and a range of other common wound 
pathogens (Acinetobacter baumannii, Enterobacter cloacae, Enterococcus faecalis, 
Escherichia coli, Klebsiella penumoniae), with MICs in the range 4-32 mg/L (bronopol) and 8-
64 mg/L (bronidox) (Supplementary Table S1).  
Whilst the CBD provides a convenient high-throughput approach to assay antibiofilm activity, 
the biofilms formed are generally small (~1 × 105 cfu) and immature, and likely substantially 
less robust in the face of antimicrobial challenge compared with those occurring in chronic 
wounds. With a view to assessing the antibiofilm activity of bronopol and bronidox against 
biofilms more representative of those found in wounds, we established larger, dual-species 
biofilms of S. aureus and Ps. aeruginosa on nitrocellulose disks. 18 These biofilms were 
challenged with bronopol and bronidox impregnated into sterile gauze at their maximum 
authorised concentrations (MACs) for safe human use (0.1% 23). Over 24 hours, both 
bronopol- and bronidox-containing dressings reduced the Ps. aeruginosa population in the 
biofilm from approximately 108 cfu/mL to below the limit of detection and achieved a ~5 log10 
reduction in the size of the S. aureus population (Figure 2A). We compared the antibiofilm 
activity of bronopol and bronidox in this biofilm model against commercial wound dressings 
and wound irrigation solutions; in terms of reducing biofilm viability, bronopol and bronidox 
substantially outperformed Inadine (povidone iodine; Systagenix), Aquacel Ag+ (silver; 
Convatec) and Prontosan (PHMB; B. Braun) (Figure 2B). 
In previous work to characterize agents capable of eradicating established biofilms of Gram-
positive pathogens, we distinguished two mechanistic classes of antibiofilm compound. One 
class primarily mediates destructuring of the biofilm matrix, 12 whilst the other involves killing 
of bacteria within the biofilm, including SONG cells. 11 To establish which mechanistic class 
bronopol and bronidox belong to, we challenged S. aureus biofilms independently with both 
agents at 16X MBEC and monitored effects on biofilm matrix integrity and bacterial viability. 
Over a 6-hour challenge, bronopol and bronidox effectively sterilized the bacterial population 
in the biofilm, with either no (bronidox) or only ~40% (bronopol) reduction in biofilm matrix 
material (Figure 3), suggesting that these compounds exert their antibiofilm action 
predominantly by killing bacteria in the biofilm. We subsequently confirmed that bronopol 
and bronidox are capable of directly killing bacteria - including SONG cells  W by performing 
time-kill studies with these compounds and both actively-growing (exponential phase) and 
non-growing (stationary phase) planktonic cultures of S. aureus. Over a 24-hour period, 
bronopol and bronidox at 4X MIC exhibited potent bactericidal activity in these experiments, 
sterilizing both growing and non-growing cultures (Figure 3B, C). By contrast, the bactericidal 
comparator antibiotic vancomycin demonstrated negligible killing of stationary phase cells. 
The ability of bronopol and bronidox to kill bacteria regardless of growth state therefore 
appears to underlie their antibiofilm ability.  
In view of the challenges associated with clinical management of biofilm-associated 
infections, it has been suggested that treatment efficacy might be improved by combining 
therapeutic approaches. 5, 24, 25 We assessed in vitro whether the antibiofilm activity of 
bronopol and bronidox could be further enhanced by combining them with existing wound 
treatment agents. In combination with all three established wound agents tested (silver 
nitrate, chlorhexidine, and cetrimide at ¼ X MBEC), bronopol and bronidox exhibited 
synergistic activity (FBEC of <0.5) against single-species biofilms of S. aureus and Ps. 
aeruginosa in the CBD (Table 1). The most synergistic combination was bronopol with 
chlorhexidine, yielding FBEC indices of 0.15 (S. aureus) and 0.25 (Ps. aeruginosa). Thus, 
bronopol and bronidox might profitably be used in conjunction with established wound 
treatment agents to further increase their antibiofilm effect.  
Finally, we examined the likelihood that resistance to bronopol and bronidox would develop 
were these agents to be deployed for the treatment of wound infection. S. aureus cultures 
were exposed to a range of sub-inhibitory concentrations of bronopol/ bronidox for 15 days, 
passaging once a day. No significant increase in MIC was detected for either compound over 
the course of the passage experiment (data not shown), indicating a low potential for 
selection of resistance, and implying that the therapeutic potential of these compounds 
should not rapidly become compromised by resistance. 
 
 
Conclusions 
To date, very few selectively toxic small molecules have been reported that are able to 
eradicate mature biofilms of both Gram-positive and Gram-negative bacteria. 26 We have 
described here the ability of the closely-related preservative agents bronopol and bronidox 
to deliver broad spectrum antibiofilm activity in multiple in vitro biofilm models. Since these 
compounds have a ~40 year history of safe use as components of personal care products, and 
exert potent antibiofilm effects at concentrations that are authorised for topical use, they 
represent promising candidates for repurposing in the treatment of chronic wound infection. 
The observation that their activity against biofilms is potentiated in the presence of 
established antibacterial wound-treatment agents suggests that bronopol and bronidox 
might also represent a useful adjunct to existing wound therapies to enhance their efficacy. 
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Figure 1. Chemical structures of bronopol and bronidox. Bronidox is the formaldehyde acetal 
of bronopol. 
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Figure 2. Antibiofilm activity of bronopol and bronidox at their maximum authorised 
concentrations (0.1% w/v) against a dual-species biofilm comprising Ps. aeruginosa and S. 
aureus (A), compared with the antibiofilm activity of wound dressings and irrigation 
solutions that are currently in clinical use (B). Results are means of at least three 
independent determinations and error bars show standard deviations.  
A 
B 
                                       
 
 
 
 
 
 
 
 
 
                                                      
A 
0 1 2 3 4 5 6 7
0
2
4
6
8
2 0 2 2 2 4
T im e  (h )
L
o
g
1
0
 
c
fu
/m
l
0 1 2 3 4 5 6 7
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
0
2
4
6
8
1 0
H o u r s
%
 b
io
fi
lm
 m
a
t
r
ix
 i
n
t
e
g
r
it
y
L
o
g
1
0
c
fu
/
b
io
film
B X
B P
B X
B P
U TC
0 1 2 3 4 5 6 7
0
2
4
6
8
2 0 2 2 2 4
T im e  (h )
L
o
g
1
0
c
fu
/m
l
B C U TC
T e tra c y c lin e
V a n c o m y c in
B ro n o p o l
B ro n id o x
Figure 3. Antibacterial and antibiofilm properties of bronopol and bronidox. (A) Effect of the 
compounds at 16X MBEC on cell viability and matrix integrity of the S. aureus SH1000 biofilm 
over six hours. Red bars represent % matrix integrity relative to the untreated control, whilst 
blue data points show Log10 cfu/ biofilm. (B) Viability of S. aureus SH1000 exponential phase 
cultures following exposure to bronopol, bronidox and comparator agents at 4X MIC. (C) 
Viability of S. aureus SH1000 stationary phase cultures following exposure to bronopol, 
bronidox and comparator agents at 4X MIC. Results are means of at least three independent 
determinations and error bars show standard deviations.  
  
 
 
 
 
 
 
  
Table 1. Fractional biofilm eradication (FBEC) indices for bronopol and bronidox in 
combination with established wound agents against single species biofilms of S. aureus and 
Ps. aeruginosa. An FBEC index of A? 0.5 is indicative of synergism. Each FBEC index was 
determined multiple times, and representative values are shown. 
 Silver Nitrate Cetrimide Chlorhexidine 
Bronidox 
S. aureus 
 
0.25 0.5 0.5 
Ps. aeruginosa 
 
0.5 0.375 0.5 
Bronopol 
S. aureus 
 
0.5 0.25 0.15 
Ps. aeruginosa 
 
0.25 0.375 0.25 
Supplementary Table 
 
 
Strain 
 
Reference/ source MIC (mg/L) 
   
Bronopol 
 
Bronidox 
 
Acinetobacter baumannii 033 Clinical isolate 4 8 
Acinetobacter baumannii 097  Clinical isolate 4 8 
Enterobacter cloacae 052 Clinical isolate 16 16 
Enterobacter cloacae 067 Clinical isolate 8 16 
Enterococcus faecalis ATCC 29212 ATCC 32 8 
Escherichia coli 32 Clinical isolate 8 16 
Escherichia coli 52 Clinical isolate 8 16 
Klebsiella pneumoniae 052 Clinical isolate 16 16 
Klebsiella pneumoniae 062 Clinical isolate 16 16 
Pseudomonas aeruginosa NCTC 10332 NCTC 8 64 
Pseudomonas aeruginosa PA14 1 16 64 
Staphylococcus aureus UAMS-1 2 16 8 
Staphylococcus aureus USA300 JE2 3 16 8 
Staphylococcus epidermidis RP62A ATCC 35984 8 8 
 
Table S1. Antibacterial activity of bronopol and bronidox against common pathogens. MICs were determined 
on a minimum of three independent occasions to ensure reproducibility.  
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